Cervical cancer screening company, TruScreen, is seeking to raise up to $2.8 million in growth capital.
The funds will be used for working capital and to capitalise on China's growth, as well as new market opportunities in Vietnam, Saudi Arabia, and Mexico.
TruScreen's portable and easy-to-use device, TruScreen Ultra, is registered in 20 countries and is already being commercially used in several countries including China and Mexico.
The company's technology has been recommended by the Chinese Obstetrics and Gynecological Association and features in the Chinese Society of Colposcopy and Cervical Pathology National Screening Guidelines.
See more
